Coronary Disease and Modifying Cardiovascular Risk in Adult Congenital Heart Disease Patients: Should General Guidelines Apply?

Awerbach, Jordan D.; Krasuski, Richard A.; Camitta, Michael G.W.

doi:10.1016/j.pcad.2018.07.018

Cited by 19 publications

(10 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prevalence of dyslipidemia, however, decreased with increasing cardiac lesion complexity. Data from the Quebec Congenital Heart Disease Database found a prevalence of dyslipidemia in 27% of patients over the age of 65, which is lower than estimates for the general population (57, 67).…”

Section: Stroke In Achdmentioning

confidence: 65%

“…Rates of smoking and recreational drug use seem to be lower in the ACHD population than in the general population (53, 57, 78). Psychosocial factors associated with increased vascular risk in other populations, however, including anxiety, depression and lower educational attainment, (10, 78, 80) are more common in people with ACHD as compared to the general population.…”

Section: Stroke In Achdmentioning

confidence: 92%

“…Population-based cohort studies suggest increased rates of diabetes and impaired glucose metabolism in ACHD as compared to healthy controls (57, 66, 68–70). The risk of metabolic syndrome also appears to be higher in the ACHD population (10, 22, 71).…”

Section: Stroke In Achdmentioning

confidence: 99%

See 2 more Smart Citations

Adults With Complex Congenital Heart Disease: Cerebrovascular Considerations for the Neurologist

et al. 2019

View full text Add to dashboard Cite

As infant and childhood mortality has decreased in congenital heart disease, this population is increasingly reaching adulthood. Adults with congenital heart disease (ACHD) represent a group with increased risk of stroke, silent brain infarcts, and vascular cognitive impairment. Cyanotic and other complex cardiac lesions confer the greatest risk of these cerebrovascular insults. ACHD patients, in addition to having an increased risk of stroke from structural cardiac issues and associated physiological changes, may have an accelerated burden of conventional vascular risk factors, including hypertension and impaired glucose metabolism. Adult neurologists should be aware of the risks of clinically evident and subclinical cerebrovascular disease in this population. We review the existing evidence on primary and secondary stroke prevention in individuals with complex congenital heart disease, and identify knowledge gaps in need of further research, including treatment of acute stroke in this population. Multisystemic genetic syndromes are outside the scope of this review.

show abstract

Section: Stroke In Achdmentioning

confidence: 65%

Section: Stroke In Achdmentioning

confidence: 92%

See 1 more Smart Citation

Adults With Complex Congenital Heart Disease: Cerebrovascular Considerations for the Neurologist

et al. 2019

View full text Add to dashboard Cite

show abstract

“…GATA binding protein 5 (GATA5) is a member of GATA family and plays an important role in CVDs as GATA5 loss-of-function mutations are closely related to congenital heart disease, atrial fibrillation, hypertension [5][6][7][8]. The latest epidemiology shows that CVD is becoming increasingly common in the elderly Adult Congenital Heart Disease population [9]. The incidence of AMI in patients with congenital heart disease is significantly higher than that in healthy controls [10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Molecular genetic study on GATA5 gene promoter in acute myocardial infarction

et al. 2021

View full text Add to dashboard Cite

Background Acute myocardial infarction (AMI) is a severe type of coronary artery disease, caused by coronary occlusion and followed by cardiac ischaemia. GATA binding protein 5 (GATA5) is an important member of GATA family and plays an important role in vascular inflammation, endothelial function, oxidative stress and cell metabolism. Previous studies have shown that the DNA sequence variants (DSVs) in GATA4 and GATA6 promoter can increase susceptibility to AMI. In this study, we explored the relationship between GATA5 promoter and AMI for the first time, hoping to provide a new genetic basis for understanding the pathogenesis of AMI. Methods GATA5 promoter was sequenced in 683 individuals (332 AMI patients and 351 controls). The transcriptional activity of the GATA5 promoter with or without DSVs in HEK-293 cells, H9c2 cells and primary neonatal rat cardiomyocytes were examined by Promega Dual-Luciferase® Reporter Assay system. Electrophoretic mobility shift assay (EMSA) was performed to explore whether the DSVs interfered with the binding of transcription factors (TFs). Results Nine mutations have been found in GATA5 promoter, eight of them evidently altered the transcriptional activity of the GATA5 promoter, five of them disrupted the binding of TFs (such as farnesoid X receptor). Furthermore, haplotype AT (across rs80197101 and rs77067995) is a dangerous haplotype of AMI. Genotype GA and allele A of rs80197101 and genotype CT and allele T of rs77067995 are the risk factors of AMI. Conclusions DSVs in GATA5 promoter can increase susceptibility to AMI. But the mechanism remains to be verified in vivo.

show abstract

“…Cardiovascular disease is a potentially serious threat to public health and has hindered social and economic development (Joseph et al, 2017; Pasquel et al, 2018). Coronary heart disease (CHD) is a common cardiovascular disease and is a main cause of disability and death (Awerbach et al, 2018; Dong et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

1-Deoxynojirimycin in Mulberry (Morus indica L.) Leaves Ameliorates Stable Angina Pectoris in Patients With Coronary Heart Disease by Improving Antioxidant and Anti-inflammatory Capacities

et al. 2019

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Stable angina pectoris (SAP) in patients with coronary heart disease (CHD) and blood stasis syndrome (BSS) is a potentially serious threat to public health. NF-κB signaling is associated with angina pectoris. 1-Deoxynojirimycin (DNJ), which is a unique polyhydroxy alkaloid, is the main active component in mulberry ( Morus indica L. ) leaves and may exhibit protective properties in the prevention of SAP in patients with CHD by affecting the NF-κB pathway. Methods: DNJ was purified from mulberry leaves by using a pretreated cation exchange chromatography column. A total of 144 SAP patients were randomly and evenly divided into experimental (DNJ treatment) and control (conventional treatment) groups. Echocardiography and ascending aortic elasticity were evaluated. The changes in inflammatory, oxidative, and antioxidant factors, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), superoxide dismutase (SOD), and malondialdehyde (MDA), were measured before and after a 4-week treatment. Self-Rating Anxiety Scale (SAS) and Hamilton Depression Scale (HAMD) scores were compared between the two groups. The improvement in SAP score, associated symptoms, and BSS was also investigated. The levels of IkB kinase (IKK), nuclear factor-kappa B (NF-κB), and inhibitor of kappa B α (IkBα) were measured by Western blot. Results: After the 4-week treatment, DNJ increased left ventricular ejection fraction and reduced left ventricular mass index, aortic distensibility, and atherosclerosis index ( p < 0.05). DNJ intervention increased angina-free walking distance ( p < 0.05). DNJ significantly reduced the levels of hs-CRP, IL-6, TNF-a, MDA, SAS, HAMD, AP, and BSS scores and increased SOD level ( p < 0.05). The total effective rate was significantly increased ( p < 0.05). The symptoms of angina attack frequency, nitroglycerin use, chest pain and tightness, shortness of breath, and emotional upset were also improved. DNJ reduced IKK and NF-κB levels and increased IkBα level ( p < 0.05). Conclusion: The DNJ in mulberry leaves improved the SAP of patients with CHD and BSS by increasing their antioxidant and anti-inflammatory capacities.

show abstract

Coronary Disease and Modifying Cardiovascular Risk in Adult Congenital Heart Disease Patients: Should General Guidelines Apply?

Cited by 19 publications

References 47 publications

Adults With Complex Congenital Heart Disease: Cerebrovascular Considerations for the Neurologist

Adults With Complex Congenital Heart Disease: Cerebrovascular Considerations for the Neurologist

Molecular genetic study on GATA5 gene promoter in acute myocardial infarction

1-Deoxynojirimycin in Mulberry (Morus indica L.) Leaves Ameliorates Stable Angina Pectoris in Patients With Coronary Heart Disease by Improving Antioxidant and Anti-inflammatory Capacities

Contact Info

Product

Resources

About